| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Spero Therapeutics, Inc.$2.28
+0.17 (+8.06%)
C 54Pipeline Score Fair Value Biotech · Commercial
Market Cap
159.81 M
EPS
0.28
P/E Ratio
11.33 $
Value Trade
2.17 M
SEC Financials
Q1 2026Dilution Risk
Revenue
258.00 K
R&D Expenses
2.91 M
Operating CF
15.86 M
Total Assets
59.02 M
Total Liabilities
6.09 M
Equity
52.93 M
D/E Ratio
12,345
1.85 %
Week
-2.82 %
1 Month
15.97 %
3 Month
24.32 %
6 Month
-80.69 %
5 Year
-79.17 %
All Time
Cash Data
Cash Position
56.13 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
7.20 M
52 Week Range
0.66 - 3.22
% held by Insiders
25.86 %
% held by Institutions
14.47 %
Enterprise Value
106.15 M
Total Shares
56.36 M
Short %
4.29 %
Float Shares
39.79 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C54
Pipeline Score $346M
Pipeline ValueFair Value
Valuation Signal9
Drugs Scored2.2x
rNPV / MCap Top 83%
Micro Cap (rank 155 of 905)
Percentile RankSpero Therapeutics, Inc. carries a moderate pipeline score (54/100), with $2.8B risk-adjusted pipeline value, led by TBP-PI-HBr in Urinary Tract Infection (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TBP-PI-HBr Small molecule | Urinary Tract Infection | Phase 3 | NCT06059846 | 49% | $1.0B | COMPLETED | 1,690 | - | - | Feb 6, 2025 | - | MEDIUM May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
tebipenem HBr | complicated urinary tract infection (cUTI),pyelonephritis | Phase 3 | 2025-10-15 | |||
tebipenem HBr | complicated urinary tract infection (cUTI),pyelonephritis | Phase 3 | 2025-10-15 | |||
tebipenem HBr | complicated urinary tract infection (cUTI),pyelonephritis | Phase 3 | 2025-10-15 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SPRO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SPRO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SPRO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SPRO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SPRO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SPRO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SPROUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
The FDA has approved Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs). This approval follows the successful PIVOT-PO trial, demonstrating non-inferiority to intravenous treatments. Utebzi aims to provide an effective outpatient treatment option, addressing the significant healthcare burden posed by cUTIs and antibiotic resistance.
Read more →SPROSpero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
Spero Therapeutics reported its first quarter 2026 results, highlighting the ongoing FDA review of its New Drug Application for tebipenem HBr, aimed at treating complicated urinary tract infections. The company maintains a cash runway into 2028, despite a net loss of $7.2 million for the quarter. The Phase 3 trial for tebipenem HBr showed promising results, positioning it as a potential oral alternative to IV treatments.
Read more →SPROSpero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
Spero Therapeutics has announced it will report its first quarter 2026 financial results and provide a business update on May 13, 2026. The report will be released after market close, and the company has stated it will not hold a conference call. This reflects Spero's commitment to keeping stakeholders informed.
Read more →SPROSpero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
Spero Therapeutics reported its financial results for Q4 and full year 2025, highlighting significant advancements in the tebipenem HBr program for cUTI. The company completed a global Phase 3 trial and resubmitted its NDA, with an FDA decision expected in late June. Spero is focused on fulfilling its licensing agreement with GSK while exploring new clinical-stage opportunities.
Read more →SPROSpero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Spero Therapeutics announced that its partner GSK has resubmitted a New Drug Application for tebipenem HBr to the FDA for treating complicated urinary tract infections. This resubmission follows positive results from the Phase 3 PIVOT-PO trial, which was halted early due to efficacy. Spero will receive a $25 million milestone payment upon submission.
Read more →SPROSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics announced the approval of 90,000 restricted stock unit awards for a new employee under its 2019 Inducement Equity Incentive Plan. This grant, approved by the Compensation Committee, is part of the company's strategy to attract talent in the clinical-stage biopharmaceutical sector. The RSUs will vest over four years, contingent on the employee's continued employment.
Read more →SPROSpero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
Spero Therapeutics reported its third quarter 2025 results, highlighting the positive Phase 3 PIVOT-PO study results for tebipenem HBr, an oral antibiotic for complicated urinary tract infections. The company is collaborating with GSK to submit an FDA filing soon, with a decision anticipated in the second half of 2026. However, the SPR720 program has been discontinued following trial reviews.
Read more →SPROSpero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
Spero Therapeutics will report its third quarter 2025 financial results on November 13, 2025. The company, which specializes in treatments for rare diseases and multi-drug resistant infections, will provide a business update following the report. No conference call is planned for this announcement.
Read more →SPROPIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Spero Therapeutics and GSK announced positive results from the Phase 3 PIVOT-PO trial for tebipenem HBr, an oral treatment for complicated urinary tract infections (cUTIs). The trial showed that tebipenem HBr is non-inferior to intravenous imipenem-cilastatin, with a similar safety profile. This could mark the first oral carbapenem antibiotic available for cUTIs in the U.S., addressing a significant healthcare need.
Read more →SPROSpero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
Spero Therapeutics announced that it will present data on tebipenem HBr at IDWeek 2025. This investigational oral carbapenem antibiotic is aimed at treating complicated urinary tract infections, including pyelonephritis. The Phase 3 PIVOT-PO trial has shown positive results, meeting its primary endpoint. GSK, Spero's partner, plans to file for FDA approval in late 2025.
Read more →SPROSpero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
Spero Therapeutics and GSK announced that the Phase 3 PIVOT-PO trial for tebipenem HBr was stopped early due to meeting its primary efficacy endpoint. The trial demonstrated non-inferiority of tebipenem HBr compared to intravenous imipenem-cilastatin in treating complicated urinary tract infections. The results will be included in a future NDA filing and presented at a scientific congress.
Read more →SPROSpero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025
Spero Therapeutics will announce its first quarter 2025 financial results and provide a business update on May 13, 2025. The company, which specializes in treatments for rare diseases and multi-drug resistant infections, will release the information after market close. No conference call will follow the announcement.
Read more →SPROSpero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
Spero Therapeutics has appointed Esther Rajavelu as President and CEO, effective May 2, 2025. Rajavelu, who has been serving as Interim CEO since January 2025, will also be nominated to the Board of Directors. The company is prioritizing its PIVOT-PO Phase 3 trial for tebipenem HBr, while former CEO Sath Shukla will step down from his position and the Board.
Read more →Competitive Position
How SPRO ranks across every disease it competes inCompetitive Position is a premium feature
See how SPRO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial